Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 11Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Hematologic Neoplasms 2Recurrence 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Dexamethasone 50Melphalan 29Cyclophosphamide 25Bortezomib 24Filgrastim 18Calcium Dobesilate 18Peripheral Blood Stem Cell Transplantation 16daratumumab 13pomalidomide 10dexamethasone acetate 8Lenalidomide 8fludarabine phosphate 7ixazomib 6dexamethasone 21-phosphate 6Whole-Body Irradiation 6Mycophenolic Acid 6venetoclax 5birtamimab 5auricularum 5Thalidomide 5Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Busulfan 5Radiotherapy 4Interferon-alpha 4Etoposide 4Carboplatin 4Biopsy 4sargramostim 3miridesap 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Blood Component Removal × Plasma cell × Clear all
NCT00651937 2020-01-14

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

M.D. Anderson Cancer Center

Phase 2 Completed
80 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT02489500 2018-09-10

VelRand

Boston Medical Center

Phase 3 Terminated
3 enrolled 11 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡